Abstract<\/p>\n
In this real\u2011world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112\/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co\u2011infection. Liver function (ALBI) and fibrosis scores (FIB\u20114, APRI) significantly improved. No serious adverse events occurred. The colbopasvir + sofosbuvir regimen showed excellent effectiveness and safety across diverse genotypes (including difficult\u2011to\u2011treat genotype 3b) and comorbidities.<\/p>\n
Introduction<\/p>\n
Chronic HCV is a major cause of cirrhosis and HCC in China. Genotype 3b is less responsive to some DAAs. Colbopasvir is a pan\u2011genotypic NS5A inhibitor approved with sofosbuvir in China. Real\u2011world data from Eastern China are needed.<\/p>\n
Methods<\/p>\n
Retrospective study at three centers (June 2023 \u2013 October 2024). Patients received colbopasvir (60 mg) + sofosbuvir (400 mg) for 12 weeks; ribavirin was added for genotype 3 or cirrhosis. Primary endpoint: SVR12 (HCV RNA <15 IU\/mL).<\/p>\n
Results<\/p>\n
\n\t
<\/p>\n
Patients\u00a0(N=113): median age 46 years, 84% male. Genotypes: 3 (58%; 3a 31%, 3b 27%), 6 (20%), 1b (13%). Cirrhosis 15%, HBV co\u2011infection 9%, HIV 1%.<\/p>\n
\n\t
\n\t
<\/p>\n
SVR12 rates: Overall 99.1% (112\/113). 100% for genotypes 3a (35\/35), 3b (30\/30), 6a (23\/23), compensated cirrhosis (17\/17), HCC (1\/1), hypertension (10\/10), diabetes (19\/19). 93.3% for genotype 1b (14\/15). 90% for HBV co\u2011infection (9\/10).<\/p>\n
\n
\n
\n\t
\n\t
<\/p>\n
Improvements: ALBI, FIB\u20114, and APRI significantly decreased from baseline to EOT and SVR12 (all p<0.05).<\/p>\n
\n\t
\n\t
<\/p>\n
Safety: No serious AEs; no discontinuations due to AEs. Common AEs: headache, nausea, fatigue.<\/p>\n
\n\t
\n\t
<\/p>\n
One failure: Genotype 1b + HBV co\u2011infection did not achieve SVR12.<\/p>\n
\n\t
<\/p>\n
Discussion<\/p>\n
This real\u2011world study confirms high efficacy<\/a> (99.1% SVR12) of colbopasvir + sofosbuvir, including 100% in 30 genotype 3b patients \u2013 higher than reported for sofosbuvir\/velpatasvir (76%). The regimen also improved liver function and fibrosis markers. Limitations: retrospective design, small HBV\/HIV subgroups, no decompensated cirrhosis, limited long\u2011term follow\u2011up.<\/p>\n Conclusions<\/p>\n Colbopasvir plus sofosbuvir is highly effective and safe for chronic HCV in Eastern China, including genotype 3b and patients with compensated cirrhosis or HBV co\u2011infection. It is a valuable option for HCV elimination.<\/p>\n Source:<\/p>\n Journal reference:<\/p>\n Ruan, L.-M., et al. (2026). Real-world Effectiveness and Safety of Coblopasvir plus Sofosbuvir in the Treatment of Chronic Hepatitis C Infection in Wenzhou, Eastern China: A Multicenter Observational Study. Journal of Clinical and Translational Hepatology. DOI: 10.14218\/jcth.2025.00673.\u00a0https:\/\/www.xiahepublishing.com\/2310-8819\/JCTH-2025-00673<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Abstract In this real\u2011world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) +…\n","protected":false},"author":2,"featured_media":194456,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[5296,35267,7708,75600,163,69985,35266,22707,12815,85,46,10108,1360],"class_list":["post-440787","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-chronic","tag-cirrhosis","tag-fibrosis","tag-hbv","tag-health","tag-hepatitis","tag-hepatitis-c","tag-hepatology","tag-hiv","tag-il","tag-israel","tag-liver","tag-research"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/440787","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=440787"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/440787\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/194456"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=440787"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=440787"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=440787"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}